Sirolimus and Secondary Skin-Cancer Prevention in Kidney Transplantation

2012582 citationsJournal Articlebronze Open Access

Authors

Sylvie Euvrard · Hospices Civils de Lyon

Emmanuel Morélon · Inserm

Lionel Rostaing · Inserm

Éric Goffin

A. Brocard · Hotel Dieu Hospital

Abstract

Switching from calcineurin inhibitors to sirolimus had an antitumoral effect among kidney-transplant recipients with previous squamous-cell carcinoma. These observations may have implications concerning immunosuppressive treatment of patients with cutaneous squamous-cell carcinomas. (Funded by Hospices Civils de Lyon and others; TUMORAPA ClinicalTrials.gov number, NCT00133887.).

Topics & Keywords

Cutaneous Melanoma Detection and Management Vascular Malformations and Hemangiomas Tuberous Sclerosis Complex Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 367, Issue 4, pp. 329-339

DOI: 10.1056/nejmoa1204166

Field-Weighted Citation Impact: 28.01